This study investigates pancreatic neuroendocrine tumors. It uses a special PET imaging agent called [18F]FluorThanatrace ([18F]FTT) to look at the expression of a protein called PARP-1 in these tumors.
The study evaluates the uptake of [18F]FTT in tumors and correlates it with the presence of certain genetic mutations. This helps researchers understand how these tumors might respond to treatments that target DNA repair mechanisms.
- Who can participate: Adults aged 18 and older with a metastatic or unresectable pancreatic neuroendocrine tumor can participate. Participants must have at least one tumor lesion that is 1.5 cm or larger.
- Study details: Participants will undergo a PET/CT scan using the investigational imaging drug [18F]FTT. The study includes a PET scan, which involves a small amount of radiation. A placebo is not used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand